Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 3:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 6,984 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Carcinoma, Breast Clear all
Active, not recruiting Phase 2 Interventional Results available

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

NCT01273610
View directory record Official record
Conditions
Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services
Interventions
Lapatinib, Trastuzumab, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
8
States / cities
Duarte, California • Lancaster, California • Pasadena, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 9, 2026, 3:10 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
36
States / cities
Scottsdale, Arizona • Tucson, Arizona • Santa Rosa, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 9, 2026, 3:10 PM EDT
Terminated Not applicable Interventional Results available

Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

NCT01012440
View directory record Official record
Conditions
Breast Cancer
Interventions
PEM Flex Solo II PET Scanner, MRI scan
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 9, 2026, 3:10 PM EDT
Terminated Phase 1 Interventional Results available

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591
View directory record Official record
Conditions
Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions
PF-06952229, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 9, 2026, 3:10 PM EDT
Recruiting Phase 2 Interventional

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast

NCT06129747
View directory record Official record
Conditions
Breast Cancer, Tumor, Breast
Interventions
Radiation Therapy
Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 9, 2026, 3:10 PM EDT
Completed Not applicable Interventional

Enhancing Shared Decision-Making in Breast Cancer

NCT03806738
View directory record Official record
Conditions
Shared Decision Making
Interventions
Intervention-specific Carevive questionnaire, Standard of Care questionnaire
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 9, 2026, 3:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Feasibility Study of Intraoperative Imaging in Breast Cancer

NCT02438358
View directory record Official record
Conditions
Breast Cancer
Interventions
LUM015, LUM 2.6 Imaging Device
Drug · Device
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 9, 2026, 3:10 PM EDT
Completed Phase 2 Interventional Results available

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

NCT04294225
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Anastrozole, Letrozole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 9, 2026, 3:10 PM EDT
Completed No phase listed Observational

Detection of Aggressive Breast Tumors Using Tc-99m-NC100692

NCT00888589
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Michael O'Connor
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 9, 2026, 3:10 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

NCT02481050
View directory record Official record
Conditions
Breast Cancer
Interventions
Eribulin Mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Denver, Colorado • Columbia, Maryland • Omaha, Nebraska + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 9, 2026, 3:10 PM EDT
Terminated Phase 2 Interventional

Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer

NCT00045591
View directory record Official record
Conditions
Breast Cancer
Interventions
Celecoxib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
74
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 9, 2026, 3:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Health SMART (Stress Management and Relaxation Training) to Improve Vaccine Immune Response

NCT00121160
View directory record Official record
Conditions
Psychological Stress
Interventions
Cognitive Behavioral Stress Management (CBSM) group intervention
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 9, 2026, 3:10 PM EDT
Recruiting Phase 2 Interventional

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

NCT04771520
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Primary Malignant Central Nervous System Neoplasm, Locally Advanced Sarcoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Primary Malignant Central Nervous System Neoplasm, Metastatic Sarcoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Avapritinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 9, 2026, 3:10 PM EDT
Not listed Phase 2 Interventional

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

NCT05025735
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions
Dapagliflozin 10Mg Tab
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 9, 2026, 3:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccination of High Risk Breast Cancer Patients - A Combined Phase I/II Feasibility-and-Efficacy Study

NCT02229084
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
P10s-PADRE/ MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide, Docetaxel
Biological · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 3:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions

NCT01367626
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 9, 2026, 3:10 PM EDT
Not listed Not applicable Interventional

Exercise Program or Health Education Program in Reducing Fatigue and Pain in Breast Cancer Survivors

NCT00336089
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor, Fatigue, Pain
Interventions
exercise intervention, educational intervention, complementary or alternative medicine procedure, fatigue assessment and management, management of therapy complications, pain therapy, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
Clayton State University
Other
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Atlanta, Georgia • Morrow, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 9, 2026, 3:10 PM EDT
Completed No phase listed Observational

Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients

NCT01639417
View directory record Official record
Conditions
Pain, Breast Cancer
Interventions
Not listed
Lead sponsor
Lynn Henry
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 9, 2026, 3:10 PM EDT
Not listed Phase 2 Interventional

Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

NCT01283789
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lapatinib and RAD-001
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 9, 2026, 3:10 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

NCT02368691
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
GTx-024
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Fort Lauderdale, Florida • Lakeland, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 9, 2026, 3:10 PM EDT
Completed No phase listed Observational

Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer

NCT01048918
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Metastatic (Stage IV) Breast Cancer, Stage III-IV Breast Cancer or Inflammatory
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 9, 2026, 3:10 PM EDT
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

NCT00003920
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cyclosporine, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody m170, yttrium Y 90 monoclonal antibody m170
Biological · Drug · Procedure + 1 more
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 9, 2026, 3:10 PM EDT
Completed No phase listed Observational

Pain in Cancer Survivors

NCT00581724
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Prostate Cancer, Head and Neck Cancer, Lung Cancer
Interventions
Telephone interview or self report survey.
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 9, 2026, 3:10 PM EDT
Withdrawn Phase 2 Interventional

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

NCT00615524
View directory record Official record
Conditions
Hormone-receptor Positive Breast Cancer
Interventions
exemestane and pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 9, 2026, 3:10 PM EDT